4 Undervalued Health Care Technology Stocks for Monday, November 11
Discover the top 4 undervalued Health Care Technology stocks for Monday, November 11 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Aneeqa Nadeem
Eunice Kim
Eunice Kim
Eunice Kim
| Share Statistics | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.1 | $202.4 | 3% |
|
| Shares Out (Mil) | 1.4 | 47.8 | 5% |
|
| Institutional Ownership | 100.0% | 79.3% | 99% |
|
| Float (Mil) | 2.4 | 39.8 | 6% |
|
| Beta | na | 1.12 | na |
|
| Avg Daily Volume (000s) | 950 | 464 | 70% |
|
| Price Change (52-week) |
(96.4%) | 45.2% | 2% |
|
| Growth | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.4%) | 11.8% | 2% |
|
| Net Income (5yr) | (17.4%) | 2.7% | 23% |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.8%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $202 | 1% |
|
| Net Income (TTM) (Mil) | ($11) | ($9) | 28% |
|
| EPS (TTM) | ($21.946) | ($0.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($1) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $18 | 12% |
|
| Enterprise Value (Q1) (Mil) | na | $178 | na |
|
| Valuation | ISPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.46 | 1.36 | 37% |
|
| P/E | na | 40.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.4 | na |
|
| Ratios | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (108.3%) | 61.6% | 2% |
|
| Net Margin | na | (24.1%) | na |
|
| ROA | (170.1%) | (21.8%) | 3% |
|
| ROE | (968.5%) | (6.7%) | 0% |
|
| Liabilities to Assets | 76.5% | 32.1% | 72% |
|
| F-Score | 2 | 4 | 7% |
|
iSpecimen Inc. did not pass any screens on 8/21/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors